1352810-99-1

Basic information

• Product Name: 3-(4-chloro-3-hydroxyphenyl)-N-(2-(diethylamino)ethyl)-4-(pyridin-4-yl)-1H-pyrazole-1-carboxamide
• Synonyms: 3-(4-chloro-3-hydroxyphenyl)-N-(2-(diethylamino)ethyl)-4-(pyridin-4-yl)-1H-pyrazole-1-carboxamide
• CAS NO: 1352810-99-1
• Molecular Weight: 413.907
• Mol File: 1352810-99-1.mol

Chemical Properties

• CAS DataBase Reference: 3-(4-chloro-3-hydroxyphenyl)-N-(2-(diethylamino)ethyl)-4-(pyridin-4-yl)-1H-pyrazole-1-carboxamide(CAS DataBase Reference)
• NIST Chemistry Reference: 3-(4-chloro-3-hydroxyphenyl)-N-(2-(diethylamino)ethyl)-4-(pyridin-4-yl)-1H-pyrazole-1-carboxamide(1352810-99-1)
• EPA Substance Registry System: 3-(4-chloro-3-hydroxyphenyl)-N-(2-(diethylamino)ethyl)-4-(pyridin-4-yl)-1H-pyrazole-1-carboxamide(1352810-99-1)

Safety Data

• Hazardous Substances Data: 1352810-99-1(Hazardous Substances Data)

Upstream product

• 73909-16-7 2-chloro-5-methylanisole 
• 85740-98-3 4-chloro-3-methoxybenzoic acid 
• 615-74-7 2-chloro-5-methylphenol 
• 1352810-90-2 3-(4-chloro-3-methoxyphenyl)-N-(2-(diethylamino)ethyl)-4-(pyridin-4-yl)-1H-pyrazole-1-carboxamide 
• 116022-18-5 methyl 4-chloro-3-methoxybenzoate 

Relevant articles and documents

Design, synthesis, and antiproliferative activity of 3,4-diarylpyrazole-1- carboxamide derivatives against melanoma cell line

Synthesis of a new series of 3,4-diarylpyrazole-1-carboxamide derivatives is described. Their antiproliferative activity against A375P human melanoma cell line was tested and the effect of substituents on the diarylpyrazole scaffold was investigated. The

Antiproliferative diarylpyrazole derivatives as dual inhibitors of the ERK pathway and COX-2

A series of 3,4-diarylpyrazole-1-carboxamide derivatives was designed and synthesized. A selected group of the target compounds was tested for in vitro antiproliferative activities over a panel of 60 cancer cell lines at the National Cancer Institute (NCI, Bethesda, MD, USA) at a single-dose concentration of 10 μm, and the four most active compounds 9a, 9l, 9n, and 10o were further tested in a five-dose testing mode to determine their IC50 values over the 60 cell lines. In addition, a selected group of target compounds were tested for inhibitory effect over cyclooxygenase isozymes. Compounds 9a, 9l, 9n, and 10o were also tested for MEK and ERK kinase inhibitory activity using Western blot assay. Compound 10o was selective toward melanoma cell line subpanel, and its antiproliferative activity may be attributed to selective cyclooxygenase-2 inhibition and ERK pathway inhibition.